首页> 外文期刊>Journal of nephrology. >Role of IgA receptors in the pathogenesis of IgA nephropathy
【24h】

Role of IgA receptors in the pathogenesis of IgA nephropathy

机译:IgA受体在IgA肾病发病机理中的作用

获取原文
获取原文并翻译 | 示例
           

摘要

Immunoglobulin A nephropathy (IgAN) or Berger's disease is the most common form of primary glomerulonephritis in the world and one of the first causes of end-stage renal failure. IgAN is characterized by the accumulation of immune complexes containing polymeric IgA1 in mesangial areas. The pathogenesis of this disease involves the deposition of polymeric and hypogalactosylated IgA1 (Gd-IgA1) in the mesangium. Quantitative and structural changes of Gd-IgA1 play a key role in the development of the disease due to functional abnormalities of two IgA receptors: the Fc alpha RI (CD89) expressed by blood myeloid cells and the transferrin receptor (CD71) on mesangial cells. Abnormal Gd-IgA1 induces release of soluble CD89, which participates in the formation of circulating IgA1 complexes. These complexes are trapped by CD71 that is overexpressed on mesangial cells in IgAN patients together with the crosslinking enzyme transglutaminase 2 allowing pathogenic IgA complex formation in situ and mesangial cell activation. A humanized mouse model expressing IgA1 and CD89 develops IgAN in a similar manner as patients. In this model, a food antigen, the gliadin, was shown to be crucial for circulating IgA1 complex formation and deposition, which could be prevented by a gluten-free diet. Identification of these new partners opens new therapeutic prospects for IgAN treatment.
机译:免疫球蛋白A肾病(IgAN)或伯杰氏病是世界上最常见的原发性肾小球肾炎,是终末期肾衰竭的首批原因之一。 IgAN的特征是在肾小球膜区积聚含有聚合IgA1的免疫复合物。这种疾病的发病机制涉及在肾小球系膜中沉积聚合物和低半乳糖基化的IgA1(Gd-IgA1)。由于两种IgA受体的功能异常,Gd-IgA1的数量和结构变化在疾病的发展中起着关键作用:两种由血液髓样细胞表达的Fc alpha RI(CD89)和在肾小球膜细胞上的转铁蛋白受体(CD71)。异常的Gd-IgA1诱导可溶性CD89释放,该CD89参与循环IgA1复合物的形成。这些复合物被CD71捕获,CD71与交联酶转谷氨酰胺酶2一起在IgAN患者的系膜细胞中过度表达,从而允许原位形成病原性IgA复合物并激活肾小球膜细胞。表达IgA1和CD89的人源化小鼠模型会以与患者相似的方式产生IgAN。在该模型中,食物抗原麦醇溶蛋白被证明对循环IgA1复合物的形成和沉积至关重要,而无麸质饮食可以防止这种情况。这些新伙伴的确定为IgAN治疗开辟了新的治疗前景。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号